📊 RGEN Key Takeaways
Is RGEN a Good Investment? Thesis Analysis
Repligen demonstrates strong financial health with excellent liquidity, conservative leverage, and robust free cash flow generation ($93.9M), supporting sustainable operations. However, extremely thin margins (6.6% net, 8.2% gross) and poor capital returns (ROE 2.3%, ROA 1.7%) coupled with disproportionate earnings growth (291.6% vs 16.4% revenue growth) raise quality-of-earnings concerns, suggesting non-operational gains or accounting benefits rather than fundamental operational improvement.
Why Buy RGEN? Key Strengths
- Solid revenue growth of 16.4% YoY demonstrates market demand
- Exceptional free cash flow generation at $93.9M with 12.7% FCF margin provides financial flexibility
- Fortress balance sheet with 8.37x current ratio, 0.26x debt-to-equity, and $566M cash position ensures financial stability
- Positive cash conversion with operating cash flow of $117.4M supporting dividend potential and reinvestment
RGEN Investment Risks to Consider
- Critically low margins (6.6% net, 8.2% gross) indicate intense competitive pressure or unfavorable product mix typical of commoditized biologics
- Earnings growth (291.6%) vastly exceeds revenue growth (16.4%), suggesting reliance on one-time gains or tax benefits rather than sustainable operations
- Weak capital efficiency with ROE of 2.3% and ROA of 1.7% indicates capital deployment problems despite profitability
- Interest coverage of 2.4x provides limited debt service cushion; any earnings decline could strain liquidity
Key Metrics to Watch
- Gross margin trend—must demonstrate stabilization or expansion to validate operational health
- Year-over-year revenue growth sustainability—confirm 16.4% growth is repeatable
- Return on equity and asset trends—watch for improvement toward industry-standard 8-12% ROE
- Operating cash flow consistency—ensure FCF generation is not dependent on working capital fluctuations
- Interest coverage ratio—monitor for deterioration that could constrain strategic flexibility
RGEN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.37x current ratio provides a solid financial cushion.
RGEN Profitability Ratios
RGEN vs Healthcare Sector
How REPLIGEN CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RGEN Overvalued or Undervalued?
Based on fundamental analysis, REPLIGEN CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RGEN Balance Sheet & Liquidity
RGEN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: REPLIGEN CORP's revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.63 reflects profitable operations.
RGEN Growth Metrics (YoY)
RGEN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $154.9M | -$654.0K | $-0.01 |
| Q2 2025 | $158.8M | $5.7M | $0.10 |
| Q1 2025 | $153.2M | $3.3M | $0.06 |
| Q3 2024 | $141.2M | -$654.0K | $-0.01 |
| Q2 2024 | $154.1M | $3.3M | $0.06 |
| Q1 2024 | $151.3M | $2.1M | $0.04 |
| Q3 2023 | $141.2M | $18.2M | $0.32 |
| Q2 2023 | $159.2M | $20.1M | $0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RGEN Capital Allocation
RGEN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for REPLIGEN CORP (CIK: 0000730272)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGEN
What is the AI rating for RGEN?
REPLIGEN CORP (RGEN) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGEN's key strengths?
Claude: Solid revenue growth of 16.4% YoY demonstrates market demand. Exceptional free cash flow generation at $93.9M with 12.7% FCF margin provides financial flexibility.
What are the risks of investing in RGEN?
Claude: Critically low margins (6.6% net, 8.2% gross) indicate intense competitive pressure or unfavorable product mix typical of commoditized biologics. Earnings growth (291.6%) vastly exceeds revenue growth (16.4%), suggesting reliance on one-time gains or tax benefits rather than sustainable operations.
What is RGEN's revenue and growth?
REPLIGEN CORP reported revenue of $738.3M.
Does RGEN pay dividends?
REPLIGEN CORP does not currently pay dividends.
Where can I find RGEN SEC filings?
Official SEC filings for REPLIGEN CORP (CIK: 0000730272) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGEN's EPS?
REPLIGEN CORP has a diluted EPS of $0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RGEN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, REPLIGEN CORP has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RGEN stock overvalued or undervalued?
Valuation metrics for RGEN: ROE of 2.3% (sector avg: 15%), net margin of 6.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RGEN stock in 2026?
Our dual AI analysis gives REPLIGEN CORP a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGEN's free cash flow?
REPLIGEN CORP's operating cash flow is $117.4M, with capital expenditures of $23.5M. FCF margin is 12.7%.
How does RGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.6% (avg: 12%), ROE 2.3% (avg: 15%), current ratio 8.37 (avg: 2).